FDA grants accelerated approval to datopotamab deruxtecan-dlnk for EGFR-mutated non-small cell lung cancer

Drug

Datroway (datopotamab deruxtecan-dlnk) · Anti-TROP2 antibody-drug conjugate

Condition

Thoracic